Becton Dickinson and Co (BDX)

NYSE
Currency in USD
172.21
-2.25(-1.29%)
Closed·
After Hours
173.00+0.79(+0.46%)
·
BDX Scorecard
Full Analysis
Management has been aggressively buying back shares
BDX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
171.87176.33
52 wk Range
163.33251.99
Key Statistics
Edit
Prev. Close
174.46
Open
173.03
Day's Range
171.87-176.33
52 wk Range
163.33-251.99
Volume
2.28M
Average Volume (3m)
2.91M
1-Year Change
-26.32%
Book Value / Share
87.91
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BDX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
221.75
Upside
+28.77%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 54 consecutive years

Becton Dickinson and Co News & Analysis

Show more

Becton Dickinson Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Becton Dickinson and Co SWOT Analysis


Strategic Spin-off
Explore BDX's plan to separate its Life Sciences division, potentially unlocking $16.7 billion in equity value and reshaping the company's future growth trajectory.
Financial Resilience
Delve into BDX's robust Q1 FY2025 performance, surpassing expectations with $5,168 million in revenue and $3.43 EPS, showcasing the company's financial strength.
Market Sentiment
Analysts offer diverse perspectives on BDX, with price targets ranging from $185 to $280, reflecting varied outlooks on the company's growth potential and strategic moves.
Growth Catalysts
Learn about BDX's opportunities in emerging markets, digital health integration, and personalized medicine, driving innovation in core medical technology segments.
Read full SWOT analysis

Becton Dickinson and Co Earnings Call Summary for Q2/2025

  • Q2 2025 EPS beat at $3.35 vs $3.28 forecast; revenue missed at $5.27B vs $5.35B expected
  • Stock fell 5.93% to $194.81 premarket; company appears undervalued with low beta of 0.38
  • 6% YoY revenue growth; adjusted gross margin improved to 54.9%, up 190 basis points
  • Full-year guidance: revenue $21.8B-$21.9B, adjusted EPS $14.34-$14.6; organic growth improvements expected
  • Challenges: research funding cuts, China procurement pressures, slow diagnostics recovery
Last Updated: 01-05-2025, 06:50 pm
Read Full Transcript

Compare BDX to Peers and Sector

Metrics to compare
BDX
Peers
Sector
Relationship
P/E Ratio
32.9x38.7x−0.4x
PEG Ratio
2.340.880.00
Price/Book
2.0x4.5x2.6x
Price / LTM Sales
2.4x3.5x3.1x
Upside (Analyst Target)
13.8%18.7%51.1%
Fair Value Upside
Unlock−12.7%8.9%Unlock

Analyst Ratings

6 Buy
11 Hold
0 Sell
Ratings:
17 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 221.75
(+28.77% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.18%
Dividend Yield
2.42%
Industry Median 0.75%
Annualised payout
4.16
Paid quarterly
5-Years Growth
+4.99%
Growth Streak

Earnings

Latest Release
May 01, 2025
EPS / Forecast
3.35 / 3.28
Revenue / Forecast
5.27B / 5.35B
EPS Revisions
Last 90 days

BDX Income Statement

FAQ

What Is the Becton Dickinson (BDX) Stock Price Today?

The Becton Dickinson stock price today is 172.21.

What Stock Exchange Does Becton Dickinson Trade On?

Becton Dickinson is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Becton Dickinson?

The stock symbol for Becton Dickinson is "BDX."

Does Becton Dickinson Pay Dividends? What’s The Current Dividend Yield?

The Becton Dickinson dividend yield is 2.42%.

What Is the Becton Dickinson Market Cap?

As of today, Becton Dickinson market cap is 49.36B.

What Is Becton Dickinson's Earnings Per Share (TTM)?

The Becton Dickinson EPS (TTM) is 5.18.

When Is the Next Becton Dickinson Earnings Date?

Becton Dickinson will release its next earnings report on 06 Aug 2025.

From a Technical Analysis Perspective, Is BDX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Becton Dickinson Stock Split?

Becton Dickinson has split 5 times.

How Many Employees Does Becton Dickinson Have?

Becton Dickinson has 74000 employees.

What is the current trading status of Becton Dickinson (BDX)?

As of 15 Jun 2025, Becton Dickinson (BDX) is trading at a price of 172.21, with a previous close of 174.46. The stock has fluctuated within a day range of 171.87 to 176.33, while its 52-week range spans from 163.33 to 251.99.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.